Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 214  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
REVIEW ARTICLE
Year : 2011  |  Volume : 3  |  Issue : 4  |  Page : 496-503  

Bacterial vaginosis: Etiology and modalities of treatment-A brief note


1 Departments of Biotechnology and Medical Engineering, National Institute of Technology, Rourkela, India
2 Department of Pharmaceutics, School of Pharmacy and Technology Management, Narsee Monjee Institute of Management Studies, Mumbai, India

Date of Submission21-Apr-2011
Date of Decision23-Jun-2011
Date of Acceptance31-Jul-2011
Date of Web Publication23-Nov-2011

Correspondence Address:
Kunal Pal
Departments of Biotechnology and Medical Engineering, National Institute of Technology, Rourkela
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0975-7406.90102

Rights and Permissions
   Abstract 

A large women population of the world is suffering from a vaginal infection commonly known as bacterial vaginosis. The disease is associated with the decrease in the lactobacilli count in the vagina. Till date, there is a lack of full proof treatment modalities for the cure of the disease. The treatment includes the use of antimicrobials and/or acidifying agents and probiotics, either separately or in combination. This note discusses about the etiology and the various present-day modalities of treatment of bacterial vaginosis.

Keywords: Antimicrobials, bacterial vaginosis, lactobacilli, probiotics, sexual intercourse, vagina


How to cite this article:
Kumar N, Behera B, Sagiri SS, Pal K, Ray SS, Roy S. Bacterial vaginosis: Etiology and modalities of treatment-A brief note. J Pharm Bioall Sci 2011;3:496-503

How to cite this URL:
Kumar N, Behera B, Sagiri SS, Pal K, Ray SS, Roy S. Bacterial vaginosis: Etiology and modalities of treatment-A brief note. J Pharm Bioall Sci [serial online] 2011 [cited 2019 Nov 17];3:496-503. Available from: http://www.jpbsonline.org/text.asp?2011/3/4/496/90102

Bacterial vaginosis (BV) is a common vaginal infection. Although the correct etiology of the disease is not known, BV is associated with the loss of the lactobacilli colonies with a subsequent overgrowth of anaerobic polymicrobials within the vaginal lumen. Of late, its occurrence has increased many-fold and is one of the most widely studied obstetric/gynecologic infectious diseases. Before going into the details of the pathophysiology of the disease, it becomes necessary to understand the normal anatomical and physiological aspects of the vagina.


   Vagina Top


Vagina may be defined as an elastic lumen, which is approximately 7.5 cm long. The elastic nature of the vagina may be attributed to the fibromuscular structure. Vaginal lumen has got three layers, viz., an outer layer of areolar tissue, a middle layer of smooth muscle, and an inner lining of stratified squamous epithelium. The lumen arises from the cervix and extends up to vaginal orifice in the perineum. The vagina runs obliquely upward and backward at an angle of 45° and lies in between the urethra and rectum. Urethra is anteriorly positioned, while rectum is posteriorly positioned to the vagina. Vagina acts as a connector between the external and internal organs of reproduction in women. In normal healthy women, the length of the anterior wall is approximately 3 inches, while its posterior wall is approximately 3.5 inches long. The vaginal opening is at the caudal end of the vulva. It is usually partially covered by the hymen, a thin membrane of connective tissue. The lubricating fluid of the vagina is secreted by the Bartholin's glands, which is located near the vaginal opening and the cervix. The pH of the vagina lies in between 3.5 and 4.5 during the period between puberty and menopause. It harbors a number of microorganisms and Lactobacillus is the predominant species.

Glycogen, an analogue of starch found in animals, is the main source of nutrients for the microbial flora residing in the lumen of the vagina. The metabolism of glycogen in the vaginal system is mediated by the estrogen hormone via estrogen receptors located in the epithelial cells covering the vaginal lumen. The activity of the estrogen receptors is dependent on the ovarian hormonal cycle. The increase in the proliferation of the epithelial cells and subsequent increase in the glycogen content during the midcycle stage of the menstrual cycle has been attributed to the increase in the estrogen levels. [1] Due to the increased proliferation rate of the epithelial cells, there is an increase in the thickness of the epithelial cell layers. [2],[3] It has been observed that the quantity of the mucus, which lines the vaginal epithelia, increases as the estrogen level increases. The increased estrogen level results in the decrease in the viscosity of the mucus, which results in a watery discharge. As the menstrual cycle enters into the latter half of the follicular phase, the production of the mucus increases by 30-folds. [1] Apart from the change in the epithelial and mucosal layers, the physiology of the vagina is also dependent on the menstrual cycle. At the time of menstruation, there is an increase in the pH of the vagina to pH = 6 at day 2 with the subsequent decrease of the same to pH = 4 at day 4. [4] The dynamic changes in the environment of the vagina during the menstrual cycle leads to the drastic changes in the ecology of the vaginal microflora. In general, it is regarded that lactobacilli species is the predominant microflora responsible for maintaining the pH of the vaginal lumen. [4] A recent study on Chinese women has also supported the same. [5] But the analysis of the DNA of the microflora from the vagina of women indicates that some women harbor Atopobium, Megasphaera, and Leptotrichia which produces the lactic acid and not the lactobacilli species. [6]

The mucus secreted in the vagina is mainly composed of glycoprotein, mucopolysaccharides (i.e., glycogen), electrolytes, and a larger fraction of water. The mucosal layer not only provides nutrients to the vaginal microflora but also acts as receptors for them. For example, tamm horsefall protein (THP) which is present both in the human urine and vaginal region promotes adhesion of  Escherichia More Details coli to these regions. Although THP is not secreted by the vaginal epithelia, their presence in the vagina has been attributed to the regular contact of the external vaginal structures with the urine. [7],[8] Lactobacilli undergo physicochemical interaction with the vaginal epithelia, which helps in the colonization of the lactobacilli and biofilm formation within the mucosal and the epithelial layer of the vagina. [8],[9] The biofilm consists of the bacterial cell layer(s) and the secretory components from the vagina. [8],[10]

The dynamic nature of the microflora is dependent on the age of the women. As the women approaches the age of 45 years, the menstrual cycle may either pause or cease forever. The condition of permanent cessation of the menstrual cycle is regarded as menopause, where there is a complete loss of follicular activity. [11] Quite often, menopause is associated with a condition where there is a remarked decrease in the vaginal secretions, especially mucus, known as post-menopausal atrophic vulvo-vaginitis. This results in the decrease in the lubrication of the vagina causing discomfort during coitus. [12] In addition, there is a decrease in the thickness of the epithelial layer thereby increasing the susceptibility of the vaginal tissue toward infection and associated irritation. [11],[12] As a result of the above conditions, there is a subsequent increase in the vaginal discomfort, dryness, burning, itching, and dyspareunia. [13] The frictional damage of the vaginal epithelia increases due to the exposure of the vaginal tissue to the moisture of the urine and is quite a common phenomenon. In addition, there is a subsequent increase in the vaginal pH in the presence of the urinary ammonia which further complicates the condition and provides an open invitation for the growth of the pathogenic microorganisms. [14]

The presence of moisture is a necessity for the proliferation of the microorganisms on any surface and the vaginal system is not an exception. [15] Sweat and transepidermal water loss is the major source of hydration of the epithelial cells. Transepidermal water loss plays an important role in the hydration of the vulva region. [15] The vaginal lumen is kept moist mainly by the vaginal secretion and to a certain extent by the urine. [16] In normal healthy women, there is an increase in the dynamic nature of the microflora with an increase in the hydration of the epithelial layer. [17] This results in the decreased permeability of the mucosal layer for the pathogenic organisms. If due to pathophysiological conditions, there is a decrease in the moisture content within the vaginal lumen and then there is a corresponding decrease in the microbial count resulting in the increase in the permeability of the barrier layer. [18] Similarly, it was found that with the increase in the moisture content around the urogenital tracts, there is a corresponding increase in the microbial activity in and around the interface of the urogenital organs and the skin. [19]

Most microbes have an optimal pH range in which they show an improved activity. Any intervention with the pH of the system may result in the growth of other microbes. The same phenomenon is also applicable for the vaginal system, which is widely populated with the lactobacilli species. The pH of the normal healthy vagina is within 3.5-4.5. The pH is mainly maintained by the production of lactic acid by the lactobacilli. Any compromise with the pH (due to pathophysiological conditions or physical activities such as insertion of contraceptive devices and intercourse) may result in the increase of the pH within the vaginal lumen, which in turn may result in the lactobacilli population and a subsequent increase in the growth of other microbe. [20] As the lactobacilli count decreases, there is a decrease in the production of lactic acid. Lactic acid has a potent anti-microbial property which helps in preventing the growth of the pathogenic microbes. [21],[22] Lactobacilli also produce antimicrobial products such as bacitracin and hydrogen peroxide which further help in the prevention of the proliferation of the pathogenic microorganisms. [23],[24] Lactobacilli have the capability to excrete the substances, which hinders their multiplication, from the vaginal lumen. [25] In addition, bacterial interference also plays an important role in checking the growth of the pathogens. Bacterial interference is a phenomena by which helpful bacteria utilizes the space, resources, and nutrients thereby not allowing the pathogens to proliferate. [26] This concept has been successfully used for the treatment/prevention of infections in vaginal region. Similar approaches have been used to decrease the infection rate in the nasal mucosa. [26]

The nutrient for the microbes is supplied by the vaginal secretions in addition to the secretions from the sweat, apocrine, and sebaceous glands. These secretions are composed of glycoproteins, polysaccharides, electrolytes, amino acids, nucleic acids, and fatty acids. [27] The metabolic products secreted by the microbes may influence the availability of the nutrients. [28] Fatty acids have shown antimicrobial activity (against Streptococcus pyogenes, Staphylococcus aureus, and skin micrococci) and may help in fine tuning the composition of the microbial flora. [22] They failed to produce substantial activity against gram-negative bacteria. [29] Apart from this, some peptides have also shown antimicrobial activity against various pathogenic bacteria, fungi, viruses, and protozoa. [30]

From the above discussion, it is now clear that the interaction among the host and the microbe may either create a mutually beneficial relationship (e.g., Lactobacillus) or may produce a deleterious effect on the host, which will lead to diseased condition and even death in severe conditions (e.g., Candida, Gardnerella, and/or trichomonas). [31] The adhesion of the pathogenic microbes to the epithelial cells is an important factor governing the colonization and/or biofilm development. This has been attributed to the competition among the natural and pathogenic microflora for the receptor sites present in the vaginal lumen. [8,32] Unfortunately, there is lack of clear understanding of the molecular basis of adherence of the lactobacilli to the epithelial cells of vagina. Some reports suggest that the adherence is mediated by the proteins present on the cell surface, [33],[34],[35] while some researchers claim that the adherence is either mediated by lipoteichoic acid [36],[37] or carbohydrates. [38]


   Microflora of the Vagina Top


Vagina provides a biosynthetic environment that has the capability to sustain a diverse ecosystem. The microflora of the vagina can be categorized as transient and resident microflora and can easily be distinguished by newer molecular methods. The transient microflora is not capable of competing with the resident microflora in establishing a permanent residence in the vagina. [39] Knowledge about the transient and resident microflora of vagina is meager as the interpretation of the available data is very difficult. Apart from this, a large number of transient organisms continuously migrate from the exogenous source (e.g., anus and urethra).

The composition of the vaginal microflora was first described by Dφderlein during the year 1892. He described the vaginal microflora as gram-positive, pleomorphic, and asporogenic bacteria, which were homogeneously distributed throughout the vaginal lumen and are often referred to as bacillus Dφderlein. [40] A study where the samples were collected from college-going students and volunteers throughout the menstrual cycle indicates that the vagina is inhabited with the anaerobic and facultative microflora. [41] Similar results were also obtained from the studies on children having age varying from 2 months to 15 years. [42] Recent studies have found that lactobacilli are the dominant microflora of the vaginal system. The other microbes include Peptococcus species, Bacteroides species, Staphylococcus epidermidis, Corynebacterium species, Peptostreptococcus species, and Eubacterium species. [43] The lactobacilli species is prevalent throughout the lifespan of women and has also been confirmed with molecular identification tools. [44] The predominance of lactobacilli is lost during various vagina diseases (e.g., bacterial vaginitis) as determined both by conventional and molecular identification techniques. [44] Among the Lactobacillus species, Lactobacillus acidophilus was considered to be the dominant microbe present in the vaginal microflora. [45] With the advent of the use of molecular identification techniques, it was found that other species (e.g., Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus iners, and Lactobacillus jenseni) may also dominate the ecosystem in the microflora. [46] The molecular identification techniques have the ability to specify the species easily in case of diverse microflora. As described earlier, vagina is a dynamic ecosystem and is a complex ecosystem having diversified species of Lactobacillus and other microbes. Eventhough the molecular identification techniques (viz., 16s r-RNA analysis, RFLP, heat shock protein) have made the life of the researchers and clinician easy, our knowledge is quite limited on the vaginal microflora. The main advantage of molecular identification techniques is its fast and efficient methods when compared with the conventional culture-based methods.


   Bacterial Vaginosis Top


BV is an infection that is associated with a group of pathogenic anaerobic microorganisms rather than a specific pathogen. It is a very common manifestation among the women population. Although the exact causative pathogen has not been figured out, it has been observed that there is a corresponding decrease in the population of the lactobacilli species. This results in the increase in the pH of the vaginal lumen due to the reduction in the lactic acid production. Apart from the lactic acid, the production of lactocin and H 2 O 2 also receives a setback. In general, the lactobacilli is replaced with the increased population of pathogenic gram-negative anaerobic bacteria such as E. coli, Gardnerella vaginalis, Mycoplasma hominis, and Mycoplasma curtisii. [47],[48] This condition may lead to several complications, which include continuous vaginal discharge, high HIV risk, malodor (fishy smell), stomach pain, abortion, infertility, preterm birth, chorioamnionitis, and urinary tract infection. [49],[50],[51]

The microflora diversity of the vagina from the patients of BV was first reported during the year 1921 by Schrφder. Till recent past, the exact causative microorganism was not known and has eluded the scientists for long, newly discovered vaginal microbes during BV were often considered as BV-causing microbes. [52] The diagnostic tests have been categorized into two categories namely clinical criteria and laboratory-based testing. [53] BV is mainly characterized by Amsel's criteria. [54] Amsel's criteria enumerates four criteria out of which at least three criteria have to be met before a woman can be declared as a patient of BV. These criteria include presence of milky homogenous watery discharge which may be gray or yellowish in color, [53] pH of vagina more than 4.5, positive amine test (fishy odor from the vaginal fluid when alkali solution is added), and the presence of clue cells. [54]

Scientists and researchers have associated BV with various factors including vaginal douching by the use of scented soaps or perfumed bubble bath and antiseptics during bath, [55] multiple sex partners and/or a new sex partner, smoking [56] and use of contraceptives (e.g., spermacides) which may increase the probability of the infection in a women.

The microflora found in the case of BV do not follow the Koch's postulates and are resistant to that approach. [52] Because the pathogenesis of BV is not clear, the management of BV is a challenging aspect for the clinicians and throughout the world, and it is becoming a very common syndrome in women in the reproductive age. [57],[58] If proper care is not taken in the early phase of BV, then it may lead to secondary complications. In pregnant women, it may either cause preterm delivery or choriamnionitis. [59],[60] The low weight of the infants (from BV patients) may also be accounted to the preterm birth. [50] The risk of contracting sexually transmitted diseases (e.g., HIV, syphilis, gonorrhea, and trichomoniasis) is higher in BV patients when compared with the healthy individual. [61]

If the patients fulfill the Amsel's criteria, various diagnostic tests are used for the confirmation of the syndrome. The whiff test is the most common test that involves the addition of potassium hydroxide solution to the vaginal discharge. The presence of a strong fishy smell indicates that the patient is suffering from BV. The microscopic examination of the vaginal smear, which is analyzed for the presence of bacteria, white blood cells and clue cells, and the presence of clue cells, indicates BV. The gram staining method, introduced by Dunkelberg in the year 1965, is also a simple method for the diagnosis of BV. [62] The method helps in the confirmation of the presence of gram-positive and gram-negative bacteria in the vaginal discharge. Recently, a scoring system (on a scale of 10) based on the presence of large gram-positive rods, small gram-negative or variable rods, and small curved gram-negative to variable rods have been reported. If the score lies in between 7 and 10, then the patient is suffering from BV. [63] The various modern analytical techniques involve the use of polymerase chain reaction and oligonucleotide probes for the determination of BV. These methods are fast, reliable, and accurate. [58] Unfortunately, these techniques are not available in all the laboratories and the clinician is forced to accept the results of the afore-mentioned diagnostic tests.


   Treatment of BV Top


Many strategies for the treatment of BV are being used by the clinicians all over the world. The treatment protocol varies from the use of synthetic drugs to the use of probiotics. In this section, an attempt will be made to explore the different modes of treatment of BV.

Antimicrobials in the treatment of BV

A lot of antimicrobial agents (e.g., ampicillin, penicillin, and metronidazole) have been used in the treatment of bacterial vaginitis. [57] Metronidazole have evolved as a drug of choice for the treatment of BV and is the widely prescribed drug. It is a nitroimidazole derivative having activity against anaerobic microbes and protozoans. It has been administered either orally or locally. Tablets of metronidazole are easily available for oral administration. Formulations for the local administration of the drug include gels and suppositories. [64],[65],[66],[67] Metronidazole and tinidazole (a chemical analogue of metronidazole) are preferred for the treatment of BV as against ampicillin. Tinidazole has a better pharmacokinetics and longer half-life than metronidazole and its recommendation for the treatment of BV is on the rise. [68] The use of ampicillin is avoided due to the emergence of ampicillin-resistant bacteria in patients with BV. It also inhibits the growth of lactobacilli. [57] The acceptance of suppositories is lower than the oral administration of the drug as they might cause irritation. [65] The insertion of suppositories into the vagina also creates problem with the patient's compliance and is worse in working women. In a recent study, it has been reported that the mode of administration of metronidazole, either orally or locally, do not have a significant difference in the eradication of the pathogenic bacteria. [67] The release of the metronidazole from the suppositories is dependent on the composition of the formulation. The release rate may be tailored by the incorporation of adjuvant. Among the metronidazole gels and lactic acid gels, for local application, lactic acid gels have been found to be more efficient and safer. The gel formulation containing a combination of both lactic acid and metronidazole has shown superior ability to recolonize the vaginal lumen with lactobacilli. The recurrence of BV is less common in patients treated with lactic acid gel when compared with patients treated with metronidazole gels. [66] This may be attributed to the hindrance and/or inhibition in the growth of the lactobacilli when metronidazole is used for the treatment and depends on the concentration of the lactobacilli. [69] Studies on the treatment of the BV have also been done with tinidazole, clindamycin, polystyrene sulfonate, and cellulose sulfate, policarbophil-carbopol acidic vaginal gel. [15],[68],[70],[71] Reports on clindamycin have suggested that it can be used in the treatment of BV and may be administered either orally or locally. [72] Intravaginal deliveries of clindamycin and metronidazole for the treatment of BV have shown that there was an improvement in the clinical symptoms of the patients within 21-30 days of the starting of the treatment. Unfortunately, the vagina was not recolonized with lactobacilli within the stated period. [64] The use of formulation consisting policarbophil-carbopol and lactic acid-chitosan mucoadhesive vaginal gels has also been reported. [13],[73] The policarbophil-carbopol gels have been found to be safe. [13] Similarly, chitosan-based lactic acid delivery gels have also been found to be safe. [73]

Unfortunately, there is an increased number of reoccurrence of BV when the synthetic antimicrobials are used and may be attributed to the development of antimicrobial resistance mechanism within the microbes. [74] Hence, the researchers and clinicians are looking for alternative methods for the treatment of BV. The various chemotherapeutic agents used for the treatment of BV and their results have been compiled in [Table 1].
Table 1: Antibiotics used for the treatment of bacterial vaginosis

Click here to view


Probiotics in the treatment of BV

The importance of probiotics in maintaining a normal health in human and animals was described by Dr. R. Fuller during the year 1989. [79] It has recently been described as "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" by the World Health Organization. [80] The lactobacilli, present in curd and different milk products, have also been categorized under probiotics. From the discussions in the previous sections, it is quite clear now that lactobacilli play an important role in the inhibition of growth, adhesion, and spread of pathogenic microbes. This has been accounted to its ability to form biofilms over the mucosal layer of the vagina and thereby compete for the nutrients and receptors with the pathogenic microbes. [40] In addition to this, they secrete lactic acid, H 2 O 2 , bacteriocins, and biosurfactants which have good antimicrobial property. Apart from the antimicrobial property of lactic acid, they help in maintaining the pH of vagina within 3.5-4.5 thereby not allowing a conducive environment for the growth of the pathogenic microbes. [20] Lactobacillus fermentum, Lactobacillus casai, L. acidophilus, and Lactobacillus iners are some of the species which have been found in vagina. [81]


   Selection Criteria for Probiotic for the Treatment of BV Top


The absence of Lactobacillus from the vagina is the specific feature of BV. [82] The major question in the treatment of BV with the use of lactobacilli as probiotics is whether it can cure BV and can inhibit the reoccurrences. Also, which species of lactobacilli can effectively inhibit the pathogens (e.g., Escherichia coli and G. vaginalis) and at the same time allow recolonization. [83] The exact species of Lactobacillus for the treatment of BV may be selected based on the antipathogenic activity of the species. The consideration of following factors should also be taken into consideration before selecting the Lactobacillus species: [84]

  1. Production of lactic acid [85]
  2. Production of H 2 O2 [86]
  3. Adhesion of the species to the epithelial layer [87]
  4. Production of antimicrobials [88],[89]



   Probiotic Treatments Available for BV Top


Sour milk and fermented milk were conventionally used for various health benefits. Elie Metchnikoff proposed the use of lactic acid-producing bacteria as probiotic, with scientific reasons, during the year 1907. [90] He was the first person to propose the use of Lactobacillus in the restoration of gastrointestinal flora. [90],[91] Various commercially available Lactobacillus-based products for the treatment of BV include yoghurt, acidophilus milk, and available Lactobacillus powder and tablets. [92]

Two types of treatment methodologies are available for the treatment of BV using probiotics. The first one includes the oral administration of the Lactobacillus, whereas the second method includes the local administration of the same in the vagina of the patient. The probiotics, when orally administered, have the natural ability to migrate to the vaginal region from the intestine via perineal and vulval skin. Studies using Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 have confirmed the phenomena. [93],[94] The treatment of pregnant women, with symptoms with BV, was carried out with yoghurt containing L. acidophilus. Vaginal douching of the patients was done with the yoghurt continuously for a week and was repeated after every 1 week's interval. The treatment helped in improving the conditions of the patients. [95] Similar results were observed when yoghurt was locally applied in the vaginal lumen. At the cessation of the study, the vaginal pH was within the normal range and the presence of Lactobacillus within the lumen was also observed. [96] This kind of treatment may result in the decrease of the watery vaginal apart from its bacterial recolonization effects. [97] In a recent study, two groups of women were treated with Lactobacillus-based products. The first group was treated with L. acidophilus suppositories, whereas the second group received a combination of L. acidophilus suppositories and oral dose of L. paracasai for a period of 3 months. Both the groups showed an increase in the colonies of Lactobacillus with a concurrent restoration of the pH. In addition to this, the group that received combination therapy showed an increase in the restoration of the intestinal microflora. [98]

The various strains of the probiotics used for the treatment of BV and their results have been compiled in [Table 2].
Table 2: Lactobacilii strains used for the treatment of bacterial vaginosis

Click here to view



   Summary Top


With the advent of increasing cases of antibiotic-resistant pathogenic microorganisms, the use of probiotics for the treatment of BV is being extensively studied. The use of probiotics for the treatment of BV has provided a ray of hope by natural and nontoxic treatment modality. [104] Apart from the above, the probiotics may offer cost-effective treatment of BV. The antimicrobial metabolites produced by the probiotics have shown great potential not only to restrict the growth of anti-microbial resistant strains but also kill the same. Although the probiotics have shown a positive effect on the treatment of BV, not only its effect has differed from patient to patient but also its reaction time against the infection is slow. Hence, it might be a good idea to use the probiotics in conjugation with the anti-microbials which will result in the synergistic activity of both the treatment modalities. A comparison on the antibiotics and probiotics therapies has been compiled in [Table 3].[106]
Table 3: Comparison of antibiotic and probiotic therapy

Click here to view


 
   References Top

1.Owen JA Jr. Physiology of the menstrual cycle. Am J Clin Nutr 1975;28:333-8.  Back to cited text no. 1
    
2.Patton DL, Thwin SS, Meier A, Hooton TM, Stapleton AE, Eschenbach DA. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 2000;183:967-73.  Back to cited text no. 2
    
3.Wagner G, Ottesen B. Vaginal physiology during menstruation. Ann Intern Med 1982;96:921-3.  Back to cited text no. 3
    
4.Eschenbach DA, Thwin SS, Patton DL, Hooton TM, Stapleton AE, Agnew K, et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis 2000;30:901-7.  Back to cited text no. 4
    
5.Shi Y, Chen L, Tong J, Xu C. Preliminary characterization of vaginal microbiota in healthy Chinese women using cultivation-independent methods. J Obstet Gynaecol Res 2009;35:525-32.  Back to cited text no. 5
    
6.Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology 2004;150:2565-73.  Back to cited text no. 6
    
7.Hawthorn LA, Bruce AW, Reid G. Ability of uropathogens to bind to Tamm Horsfall protein-coated renal tubular cells. Urol Res 1991;19:301-4.  Back to cited text no. 7
    
8.Otero CM, Nader-Macías EM. Lactobacillus adhesion to epithelial cells from bovine vagina. Commun Curr Res Educ Top Trends App Microbiol 2007;2:749-57.  Back to cited text no. 8
    
9.Busscher HJ, Weerkamp AH. Specific and non-specific interactions in bacterial adhesion to solid substrata. FEMS Microbiol Lett 1987;46:165-73.  Back to cited text no. 9
    
10.Bibel DJ, Aly R, Lahti L, Shinefield HR, Maibach HI. Microbial adherence to vulvar epithelial cells. J Med Microbiol 1987;23:75-82.  Back to cited text no. 10
    
11.Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet 2006;273:195-202.  Back to cited text no. 11
    
12.Kamarashev JA, Vassileva SG. Dermatologic diseases of the vulva. Clin Dermatol 1997;15:53-65.  Back to cited text no. 12
    
13.Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52 Suppl 1:S46-52.  Back to cited text no. 13
    
14.Andersen PH, Bucher AP, Saeed I, Lee PC, Davis JA, Maibach HI. Faecal enzymes: In vivo human skin irritation. Contact Dermatitis 1994;30:152-8.  Back to cited text no. 14
    
15.Warren R, Bauer A, Greif C, Wigger-Alberti W, Jones MB, Roddy MT, et al. Transepidermal water loss dynamics of human vulvar and thigh skin. Skin Pharmacol Physiol 2005;18:139-43.  Back to cited text no. 15
    
16.Faergemann J, Aly R, Wilson DR, Maibach HI. Skin occlusion: effect on Pityrosporum orbiculare, skin PCO2, pH, transepidermal water loss, and water content. Arch dermatol Res 1983;275:383-7.  Back to cited text no. 16
    
17.Freinkel RK, Shen Y. The origin of free fatty acids in sebum. II. Assay of the lipases of the cutaneous bacteria and effects of pH. J Invest Dermatol 1969;53:422-7.  Back to cited text no. 17
    
18.Elias P. The skin barrier as an innate immune element. Semin Immunopathol 2007;29:3-14.  Back to cited text no. 18
    
19.Farage M, Bramante M, Otaka Y, Sobel J. Do panty liners promote vulvovaginal candidiasis or urinary tract infections?: A review of the scientific evidence. Eur J Obstet Gynecol Reproduct Biol 2007;132:8-19.  Back to cited text no. 19
    
20.Aroutcheva A, Gariti D, Simon M, Shott S, Faro J, Simoes JA, et al. Defense factors of vaginal lactobacilli. Am J Obstet Gynecol 2001;185:375-9.  Back to cited text no. 20
    
21.Nieman C. Influence of trace amounts of fatty acids on the growth of microorganisms. Bactorial Rev1954;18:147-63.  Back to cited text no. 21
    
22.Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother 1972;2:23-8.  Back to cited text no. 22
    
23.Brook I. Bacterial Interference. Crit Rev Microbiol 1999;25:155-72.  Back to cited text no. 23
    
24.Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 2002;4:319-24.  Back to cited text no. 24
    
25.Osset J, Bartolomé RM, García E, Andreu A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001;183:485-91.  Back to cited text no. 25
    
26.Lina G, Boutite F, Tristan A, Bes M, Etienne J, Vandenesch F. Bacterial competition for human nasal cavity colonization: role of Staphylococcal agr alleles. Appl Environ Microbiol 2003;69:18-23.  Back to cited text no. 26
    
27.Pommerenke WT, Taylor PW Jr. Antibacterial properties of vaginal and cervical secretions and amniotic fluid. Ann Ostet Ginecol 1953;75:891-9.  Back to cited text no. 27
    
28.Cavallo G. Vaginal microbial flora and infectious pathology. G Batteriol Virol Immunol 1987;80:277-95.  Back to cited text no. 28
    
29.Ouattara B, Simard RE, Holley RA, Piette GJ, Bégin A. Antibacterial activity of selected fatty acids and essential oils against six meat spoilage organisms. Int J Food Microbiol 1997;37:155-62.  Back to cited text no. 29
    
30.Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95.  Back to cited text no. 30
    
31.Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 2000;68:6511-8.  Back to cited text no. 31
    
32.Boris S, Suárez JE, Vázquez F, Barbés C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect Immun 1998;66:1985-9.  Back to cited text no. 32
    
33.Coconnier MH, Klaenhammer TR, Kernéis S, Bernet MF, Servin AL. Protein-mediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. Appl Environ Microbiol 1992;58:2034-9.  Back to cited text no. 33
    
34.Conway PL, Kjelleberg S. Protein-mediated adhesion of Lactobacillus fermentum strain 737 to mouse stomach squamous epithelium. J Gen Microbiol 1989;135:1175-86.  Back to cited text no. 34
    
35.Bernet MF, Brassart D, Neeser JR, Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 1993;59:4121-8.  Back to cited text no. 35
    
36.Sherman LA, Savage DC. Lipoteichoic acids in Lactobacillus strains that colonize the mouse gastric epithelium. Appl Environ Microbiol 1986;52:302-4.  Back to cited text no. 36
    
37.Granato D, Perotti F, Masserey I, Rouvet M, Golliard M, Servin A, et al. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Appl Environ Microbiol 1999;65:1071-7.  Back to cited text no. 37
    
38.Neeser JR, Granato D, Rouvet M, Servin A, Teneberg S, Karlsson KA. Lactobacillus johnsonii La 1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 2000;10:1193-9.  Back to cited text no. 38
    
39.Lowbury EJ, Lilly HA, Bull JP. Disinfection of Hands: Removal of Transient Organisms. Br Med J 1964;2:230-3.  Back to cited text no. 39
    
40.Lepargneur JP, Rousseau V. Protective role of the Doderleïn flora. J Gynecol Obstet Biol Reprod (Paris) 2002;31:485-94.  Back to cited text no. 40
    
41.Bartlett JG, Onderdonk AB, Drude E, Goldstein C, Anderka M, Alpert S, et al. Quantitative Bacteriology of the vaginal flora. J Infect Dis 1977;136:271-7   Back to cited text no. 41
    
42.Hammerschlag MR, Alpert S, Onderdonk AB, Thurston P, Drude E, McCormack WM, et al. Anaerobic microflora of the vagina in children. Am J Obstet Gynecol 1978;131:853-6.  Back to cited text no. 42
    
43.Bartlett JG, Onderdonk AB, Drude E, Goldstein C, Anderka M, Alpert S, et al. Quantitative bacteriology of the vaginal flora J Infect Dis 1977;136:271-7.  Back to cited text no. 43
    
44.Stoyancheva G, Danova S, Boudakov IY. Molecular identification of vaginal lactobacilli isolated from Bulgarian women. Antonie Van Leeuwenhoek 2006;90:201-10.  Back to cited text no. 44
    
45.Lachlak N, Ageron E, Zampatti O, Michel G, Grimont PA. Composition of the Lactobacillus acidophilus complex isolated from vaginal flora. New Microbiol 1996;19:123-32.  Back to cited text no. 45
    
46.Vásquez A, Jakobsson T, Ahrné S, Forsum U, Molin G. Vaginal Lactobacillus flora of healthy Swedish women. J Clin Microbiol 2002;40:2746-9.  Back to cited text no. 46
    
47.Hillier S. The complexity of microbial diversity in bacterial vaginosis. N Eng J Med 2005;353:1886-7.  Back to cited text no. 47
    
48.Hill GB. The microbiology of bacterial vaginosis. Am J Obste Gynecol 1993;169:450-4.  Back to cited text no. 48
    
49.Darwish A, Elnshar EM, Hamadeh SM, Makarem MH. Treatment options for bacterial vaginosis in patients at high risk of preterm labor and premature rupture of membranes. J Obstet Gynaecol Res 2007;33:781-7.  Back to cited text no. 49
    
50.Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995;333:1737-42.  Back to cited text no. 50
    
51.Afrakhteh M, Mahdavi A. Bacterial vaginosis and urinary tract infection. J Obstet Gynecol India 2007;57:513-6.  Back to cited text no. 51
    
52.Hillier SL. The complexity of microbial diversity in bacterial vaginosis. N Engl J Med 2005;353:1886-7.  Back to cited text no. 52
    
53.Money D. The laboratory diagnosis of bacterial vaginosis. Can J Infect Dis Med Microbiol 2005;16:77-9.  Back to cited text no. 53
    
54.Wang J. Bacterial vaginosis. Primary Care Update for OB/GYNS. Prim Care Update Ob Gyns 2000;7:181-5.  Back to cited text no. 54
    
55.Klebanoff MA, Nansel TR, Brotman RM, Zhang J, Yu KF, Schwebke JR, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis 2010;37:94-9.  Back to cited text no. 55
    
56.Ryckman KK, Simhan HN, Krohn MA, Williams SM. Predicting risk of bacterial vaginosis: The role of race, smoking and corticotropin-releasing hormone-related genes. Mol Hum Reprod 2009;15:131-7.  Back to cited text no. 56
    
57.Spiegel CG. Bacterial vaginosis. Clin Microbiol Rev 1991;4:485-502.  Back to cited text no. 57
    
58.Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005;353:1899-911.  Back to cited text no. 58
    
59.Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995;333:1737-42.  Back to cited text no. 59
    
60.Aruna K, Jyoti K. Role of bacterial vaginosis in preterm labor. J Obstet Gynecol India 2007;57:413-6.  Back to cited text no. 60
    
61.Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. Aids 1998;12:1699-706.  Back to cited text no. 61
    
62.Dunkelberg WE Jr. Diagnosis of hemophilus vaginalis vaginitis by gram-stained smears. Am J Obstet Gynecol1965;91:998.  Back to cited text no. 62
    
63.Joesoef M, Schmid G, Hillier S. Bacterial vaginosis: Review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999;28 Suppl 1:S57-65.  Back to cited text no. 63
    
64.Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283-9.  Back to cited text no. 64
    
65.Adegboye T, Itiola O. Physical and release properties of metronidazole suppositories. Trop J Pharm Res 7:887-96.  Back to cited text no. 65
    
66.Decena DC, Co JT, Manalastas RM Jr, Palaypayon EP, Padolina CS, Sison JM, et al. Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. J Obstet Gynaecol Res 2006;32:243-51.  Back to cited text no. 66
    
67.Mitchell CM, Hitti JE, Agnew KJ, Fredricks DN. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: Impact on fastidious bacteria. BMC Infect Dis 2009;9:89.  Back to cited text no. 67
    
68.Dickey LJ, Nailor MD, Sobel JD. Guidelines for the treatment of bacterial vaginosis: Focus on tinidazole. Ther Clin Risk Manag 2009;5:485-9.  Back to cited text no. 68
    
69.Simoes JA, Aroutcheva AA, Shott S, Faro S. Effect of metronidazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gyneco 2001;9:41-5.  Back to cited text no. 69
    
70.Nyirjesy P, McIntosh MJ, Gattermeir DJ, Schumacher RJ, Steinmetz JI, Joffrion JL. The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with bacterial vaginosis. Am J Obstet Gynecol 2006;194:1277-82.  Back to cited text no. 70
    
71.Simoes JA, Citron DM, Aroutcheva A, Anderson RA Jr, Chany CJ 2 nd , Waller DP, et al. Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis. Antimicrob Agents Chemother 2002;46:2692-5.  Back to cited text no. 71
    
72.McGregor JA, French JI, Jones W, Milligan K, McKinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: Results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994;170:1048-59.  Back to cited text no. 72
    
73.Bonferoni MC, Giunchedi P, Scalia S, Rossi S, Sandri G, Caramella C. Chitosan gels for the vaginal delivery of lactic acid: Relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech 2006;7:104.  Back to cited text no. 73
    
74.Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004;191:1124-9.  Back to cited text no. 74
    
75.Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011;204:211.e1-6.  Back to cited text no. 75
    
76.Yasin B, Pang M, Lehrer RI, Wagar EA. Activity of Novispirin G-10, a novel antimicrobial peptide against Chlamydia trachomatis and vaginosis-associated bacteria. Exp M Pathol 2003;74:190-5.  Back to cited text no. 76
    
77.Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101:516-22.  Back to cited text no. 77
    
78.Donders G, Bellen G, Ausma J, Verguts L, Vaneldere J, Hinoul P, et al. The effect of antifungal treatment on the vaginal flora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis. Eur J Clin Microbiol Infect Dis 2011;30:59-63.  Back to cited text no. 78
    
79.Ouwehand A, Salminen S, Isolauri E. Probiotics: An overview of beneficial effects. Antonie Van Leeuwenhoek 2002;82:279-89.  Back to cited text no. 79
    
80.Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003;16:658-72.  Back to cited text no. 80
    
81.Burton JP, Cadieux PA, Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl Environ Microbiol 2003;69:97-101.  Back to cited text no. 81
    
82.Hillier SL, Krohn MA, Rabe LK, Klebanoff SJ, Eschenbach DA. The normal vaginal flora, H2O2-producing lactobacilli, and bacterial vaginosis in pregnant women. Clin Infect Dis 1993;16 Suppl 4:S273-81.  Back to cited text no. 82
    
83.Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol 2003;189:1202-8.  Back to cited text no. 83
    
84.Mclean N, Rosenstein IJ. Characterisation and selection of a Lactobacillus species to re-colonise the vagina of women with recurrent bacterial vaginosis. J Med Microbiol 2000;49:543-52.  Back to cited text no. 84
    
85.Juárez Tomás MS, Ocaña VS, Wiese B, Nader-Macías ME. Growth and lactic acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. J Med Microbiol 2003;52:1117-24.  Back to cited text no. 85
    
86.Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989;27:251-6.  Back to cited text no. 86
    
87.Boris S, Suarez JE, Vazquez F, Barbes C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect Immun 1998;66:1985-9.  Back to cited text no. 87
    
88.Hamdan IY, Mikolajcik EM. Acidolin: An antibiotic produced by Lactobacillus acidophilus. J Antibiot (Tokyo) 1974;27:631-6.  Back to cited text no. 88
    
89.Abee T, Klaenhammer TR, Letellier L. Kinetic studies of the action of lactacin F, a bacteriocin produced by Lactobacillus johnsonii that forms poration complexes in the cytoplasmic membrane. Appl Environ Microbiol 1994;60:1006-13.  Back to cited text no. 89
    
90.Anukam K, Reid G. Probiotics: 100 years (1907-2007) after Elie Metchnikoff's Observation. Kingsley C Anukam 2008:21.  Back to cited text no. 90
    
91.Sieber R, Dietz U. Lactobacillus acidophilus and yogurt in the prevention and therapy of bacterial vaginosis. Int Dairy J 1998;8:599-607.  Back to cited text no. 91
    
92.Hughes VL, Hillier SL. Microbiologic characteristics of Lactobacillus products used for colonization of the vagina. Obstet Gynecol 1990;75:244-8.  Back to cited text no. 92
    
93.Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immun Med Microbiol 2001;30:49-52.  Back to cited text no. 93
    
94.Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microb Infect 2006;8:1450-4.  Back to cited text no. 94
    
95.Tasdemir M, Tasdemir I, Tasdemir S, Tavukcuoglu S. Alternative treatment for bacterial vaginosis in pregnant patients; restoration of vaginal acidity and flora. Arch AIDS Res 1996;10:239-41.  Back to cited text no. 95
    
96.Neri A, Sabah G, Samra Z. Bacterial vaginosis in pregnancy treated with yoghurt. Acta Obstet Gynecol Scand 1993;72:17-9.  Back to cited text no. 96
    
97.Chimura T, Funayama T, Murayama K, Numazaki M. Ecological treatment of bacterial vaginosis. Jap J Antibio 1995;48:432-6.  Back to cited text no. 97
    
98.Delia A, Morgante G, Rago G, Musacchio MC, Petraglia F, De Leo V. [Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillus acidofilus in the treatment of vaginosis and in the prevention of recurrent vaginitis]. Minerva Ginecol 2006;58:227-31.  Back to cited text no. 98
    
99.Ehrström S, Daroczy K, Rylander E, Samuelsson C, Johannesson U, Anzén B, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 2010;12:691-9.  Back to cited text no. 99
    
100.Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JD, Reid G. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gynecol Obstet 2010;111:245-8.  Back to cited text no. 100
    
101.Srinivasan U, Misra D, Marazita ML, Foxman B. Vaginal and oral microbes, host genotype and preterm birth. Med Hypotheses 2009;73:963-75.  Back to cited text no. 101
    
102.Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: A double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010;203:120.e1-6.  Back to cited text no. 102
    
103.Marcone V, Rocca G, Lichtner M, Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynecol Obstet 2010;110:223-6.  Back to cited text no. 103
    
104.Dover SE, Aroutcheva AA, Faro S, Chikindas ML. Natural antimicrobials and their role in vaginal health: A short review. Int J Probiotics Prebiotics 2008;3:219-30.  Back to cited text no. 104
    
105.Matu MN, Orinda GO, Njagi EN, Cohen CR, Bukusi EA. In vitro inhibitory activity of human vaginal lactobacilli against pathogenic bacteria associated with bacterial vaginosis in Kenyan women. Anaerobe 2010;16:210-5.  Back to cited text no. 105
    
106.McMillan A, Dell M, Zellar MP, Cribby S, Martz S, Hong E, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 2011;86:58-64.  Back to cited text no. 106
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3]


This article has been cited by
1 Olegusella massiliensis gen. nov., sp. nov., strain KHD7 T , a new bacterial genus isolated from the female genital tract of a patient with bacterial vaginosis
Khoudia Diop,Awa Diop,Florence Bretelle,Frédéric Cadoret,Caroline Michelle,Magali Richez,Jean-François Cocallemen,Didier Raoult,Pierre-Edouard Fournier,Florence Fenollar
Anaerobe. 2017; 44: 87
[Pubmed] | [DOI]
2 Biotherapeutic agents and vaginal health
F.H. Al-Ghazzewi,R.F. Tester
Journal of Applied Microbiology. 2016; 121(1): 18
[Pubmed] | [DOI]
3 Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case–control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis
Nadia Recine,Ettore Palma,Lavinia Domenici,Margherita Giorgini,Ludovica Imperiale,Carolina Sassu,Angela Musella,Claudia Marchetti,Ludovico Muzii,Pierluigi Benedetti Panici
Archives of Gynecology and Obstetrics. 2016; 293(1): 101
[Pubmed] | [DOI]
4 Design of novel urogenital pharmabiotic formulations containing lactobacilli, salivaricin CRL 1328 and non-microbial compounds with different functionalities
Esteban Vera Pingitore,María Silvina Juárez Tomás,Birgitt Wiese,María Elena Fátima Nader-Macías
Drug Development and Industrial Pharmacy. 2014; : 1
[Pubmed] | [DOI]
5 Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis
Vinay K. Singh,Arfat Anis,Indranil Banerjee,Krishna Pramanik,Mrinal K. Bhattacharya,Kunal Pal
Materials Science and Engineering: C. 2014;
[Pubmed] | [DOI]
6 Gelatin-carbohydrate phase-separated hydrogels as bioactive carriers in vaginal delivery: Preparation and physical characterizations
Vinay Kumar Singh,Sai Sateesh Sagiri,Kunal Pal,Shankar M. Khade,Dillip K. Pradhan,Mrinal K. Bhattacharya
Journal of Applied Polymer Science. 2014; : n/a
[Pubmed] | [DOI]
7 Curative effect of the probiotic strainLactobacillus fermentumL23 in a murine model of vaginal infection byGardnerella vaginalis
M. Daniele,L. Pascual,L. Barberis
Letters in Applied Microbiology. 2014; : n/a
[Pubmed] | [DOI]
8 Research Gaps in Defining the Biological Link between HIV Risk and Hormonal Contraception
Kerry Murphy,Susan C. Irvin,Betsy C. Herold
American Journal of Reproductive Immunology. 2014; : n/a
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Vagina
    Microflora of th...
   Bacterial Vaginosis
   Treatment of BV
    Selection Criter...
    Probiotic Treatm...
   Summary
    References
    Article Tables

 Article Access Statistics
    Viewed4264    
    Printed144    
    Emailed3    
    PDF Downloaded175    
    Comments [Add]    
    Cited by others 8    

Recommend this journal